Literature DB >> 646247

Carcinoembryonic antigen assay of ascites and detection of malignancy.

M S Loewenstein, R A Rittgers, A E Feinerman, H Z Kupchik, B R Marcel, R S Koff, N Zamcheck.   

Abstract

Levels of carcinoembryonic antigen (CEA) activity were measured in 105 unselected samples of ascitic fluid submitted for routine cytologic analysis to ascertain whether this assay was useful in the detection of malignancy. The highest CEA level found in the 70 specimens of "benign" ascites was 10 ng/ml. Using values greater than 10 ng/ml as indicating a cancerous effusion, CEA assay successfully detected 14 of the 29 malignant ascites studied. Cytology, on the other hand, detected only 12 of these fluids. Combining the two methods increased the yield to 20. The CEA assay alone thus detected more than one fourth of these malignant fluids. The assay was particularly useful in detecting malignant transudates, nearly half of which had elevated CEA levels despite negative cytologic findings. The CEA assay of ascites thus showed promise as an adjunct to cytology in the detection of malignant ascites when used as part of a complete clinical and laboratory assessment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646247     DOI: 10.7326/0003-4819-88-5-635

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

2.  [Carcinoembryonic antigen (CEA) and CEA-like activities in ascites and pleura-effusions (author's transl)].

Authors:  H Eimermacher; W Tinnefeld; H Pressler; P Schuster; H K Beyer
Journal:  Klin Wochenschr       Date:  1979-06-01

3.  Palliative treatment of malignant ascites: profile of catumaxomab.

Authors:  Lila Ammouri; Eric E Prommer
Journal:  Biologics       Date:  2010-05-25

4.  Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis.

Authors:  Sung Jin Kang; Kwang Soo Kim; Yoon Suk Ha; So Young Huh; Ji Hyun Lee; Jong Kuk Kim; Min Jeong Kim
Journal:  J Clin Neurol       Date:  2010-03-26       Impact factor: 3.077

5.  Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours.

Authors:  A Twijnstra; A P van Zanten; A A Hart; B W Ongerboer de Visser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

6.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03

7.  Tumour associated antigens in diagnosis of serous effusions.

Authors:  J Mezger; W Permanetter; A L Gerbes; W Wilmanns; R Lamerz
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

8.  Diagnosis of malignant ascites. Comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference.

Authors:  M Prieto; M J Gómez-Lechón; M Hoyos; J V Castell; D Carrasco; J Berenguer
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

9.  1H-NMR spectroscopy metabonomics of reactive, ovarian carcinoma and hepatocellular carcinoma ascites.

Authors:  Lucio Zennaro; Lorenzo Nicolè; Paola Vanzani; Filippo Cappello; Ambrogio Fassina
Journal:  Pleura Peritoneum       Date:  2020-05-12

10.  Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.

Authors:  Hae Kyung Lee; Hiun Suk Chae; Jin Soo Kim; Hyung Keun Kim; Young Seok Cho; Sang Young Rho; Jin-Hyoung Kang; Seok Goo Cho; Hong Seok Jang; Kyungja Han
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.